Doxorubicin hyaluronic acid complex

Drug Profile

Doxorubicin hyaluronic acid complex

Alternative Names: Doxorubicin hyaluronan acid complex; HA-doxorubicin; Hyaluronan doxorubicin complex; Hyaluronic acid + doxorubicin; Hyaluronic acid doxorubicin complex; HyDOX

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Monash University
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 07 Mar 2013 Suspended - Phase-I/II for Cancer (metastatic disease, treatment-resistant, late-stage disease) in Australia (IV)
  • 14 Aug 2003 Phase-I/IIa clinical trials in Cancer (metastatic disease, treatment-resistant, late-stage disease) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top